Dr. Kibar is an entrepreneur and an inventor, with numerous successful start-ups under his belt. He was the Scientific Founder of Genoptix (an oncology diagnostics company), which went public in 2007 (NASDAQ: GXDX) and was later acquired by Novartis in 2011. Dr. Kibar was also a Co-Founder of E-Tenna, whose assets relating to wireless antennas were acquired by Titan and assets relating to thermal management of microprocessors by Intel. He was a Vice President at Pequot Capital's venture capital and private equity team.

Dr. Kibar received his MS and PhD, specializing in Biophotonics and Optoelectronics, from University of California, San Diego, a BS in Electrical Engineering from Caltech and a BA in Mathematical Economics from Pomona College.

Troy Cox, former CEO of Foundation Medicine, is striving to make a difference in patients’ lives by serving on the boards of innovative growth companies in the Biotech, Genetics, Diagnostic, and Digital Health industries. As President and Chief Executive Officer, Mr. Cox led Foundation Medicine (NASDAQ: FMI) through the acquisition by Roche for $5.3 billion in 2018. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles of increasingly broad accountabilities including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. Mr. Cox received his MBA at the University of Missouri and BBA in Finance from the University of Kentucky. He is Chairman of Sophia Genetics (Series F), Vice Chairman of LetsGetChecked (Series C), Board Director at Zymeworks (NYSE: ZYME) and CM Life Sciences II as well as non-profits Massachusetts BioTechnology Council (MassBio) and Dream Foundation.

Susannah Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019 just ahead of the Company’s initial public offering. At Royalty Pharma, Ms. Gray led the Company’s efforts to maximize its financial capabilities. In her career at Royalty Pharma, she increased the debt facilities from approximately $200 million to $7 billion, and was responsible for over $20 billion in total financing. She also raised $2.0 billion equity capital for the Company.

Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a Managing Director and the Senior Analyst covering the healthcare sector for CIBC World Market’s high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University. Ms. Gray currently serves on the board of directors of Susan G. Komen and is on the board of trustees at Wesleyan University.

Karen McGinnis has served as a member of the Board of Directors since March 2021. Ms. McGinnis has over 30 years of experience in executive operational and finance roles at international public companies. She most recently served as Vice President & Chief Accounting Officer of Illumina, Inc., a leader in sequencing- and array-based solutions for genetic and genomic analysis from November 2017 until her retirement on April 2, 2021. Prior to joining Illumina, Ms. McGinnis served from February 2016 to April 2017 as Director, President and Chief Executive Officer of Mad Catz Interactive, Inc. a global provider of innovative interactive entertainment products. From June 2013 through February 2016, Ms. McGinnis served as Mad Catz’ Chief Financial Officer. Prior to joining Mad Catz, Ms. McGinnis served from November 2009 through May 2013 as Chief Accounting Officer of Cymer, Inc., the world’s leading supplier of light sources used in the photolithography process for semiconductor or chip manufacturing until its acquisition in 2013. Ms. McGinnis also served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. Ms. McGinnis also serves as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC), Absci Corporation (Nasdaq: ABSI) and Sonendo, Inc. (NYSE: SONX). Ms. McGinnis is a Certified Public Accountant and earned her BBA in Accounting from the University of Oklahoma.

Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of MiNA Therapeutics, AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies. Beginning his career as a practicing physician, Dr. Roshwalb understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate biotech advances into clinical practice. Dr. Roshwalb has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, he was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Dr. Roshwalb started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, he was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident. Dr. Roshwalb obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a BA from Columbia University.

Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments. Prior to joining T. Rowe, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company, where he covered global pharmaceutical equities.

Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University.

Mr. Samikoglu is a public and private investor, entrepreneur and a former investment banker. Prior to Biosplice, he was the Co-Founder, Portfolio Manager and a Partner of Greywolf Capital Management LP, a New York-based investment fund managing capital in different strategies. Prior to forming Greywolf, he was the Director of Research and a Portfolio Manager of Goldman Sachs’ Special Situations Investing Group. Mr. Samikoglu began his career at Goldman, Sachs & Co. where he spent nine years, both as a proprietary investor and as an investment banker.

Mr. Samikoglu received his MBA from Harvard Business School and his BA in Economics from Hamilton College.

Dr Finian Tan is a venture capitalist, entrepreneur, and the founder and current chairman of Vickers Venture Partners, an international venture capital firm with a presence in Singapore, Shanghai, New York, Hong Kong, Silicon Valley, and San Francisco. Before he started Vickers, Dr. Tan was Managing Director and head of the Credit Suisse First Boston’s (“CSFB”) group of banks in Singapore and Malaysia, a role he took on after leaving his position as the Founding Partner and Managing Director of Silicon Valley venture capital firm Draper Fisher Jurvetson ePlanet for Asia, where he made an early and probably his most famous investment in Chinese tech giant Baidu. Prior to this, in 1997, Dr. Tan served as Deputy Secretary of the Ministry of Trade and Industry for the Singapore Government.

Dr. Tan received his Doctor of Philosophy from Cambridge University on the Shell/Cambridge Scholarship. He received his B.Sc. Degree in Engineering from the University of Glasgow, where he also won all the academic awards available for the examinations, including an award for being the top student for his course, as well as the most distinguished graduate award.

Nathan Akhavan serves as an Associate Research Analyst for Eventide, and an Associate for Eventide’s private fund. Mr. Akhavan has research responsibilities for healthcare investments at Eventide.

Prior to joining Eventide, Mr. Akhavan worked at Gryphon Partners in New York, where he served as an Investment Analyst covering the sectors of healthcare, technology, and sustainability. Prior to Gryphon, he conducted research on pancreatic cancer and oncogenes at MD Anderson Cancer Center and Columbia University Medical Center.

Mr. Akhavan holds an MBA from New York University’s Stern School of Business and a BA with honors from Yeshiva University in Biology.

Chidozie Ugwumba serves as Managing Partner of SymBiosis, a venture capital firm focused on investments in biotherapeutics. At SymBiosis, Mr. Ugwumba leads sourcing, due diligence, and execution of investments, and serves as an advisor to SymBiosis’ portfolio companies. He has led numerous investments in therapeutics companies in the US and Europe, across disease areas including CNS, cardiac, dermatology, GI, infectious disease, and oncology, and across modalities such as precision medicine, and cell, gene, and regenerative therapy. Prior to SymBiosis, Mr. Ugwumba led the Direct and Impact Investment Group of WIT, LLC—an investment management entity affiliated with Walton Enterprises—and worked on the Private Credit and Infrastructure teams at Partners Group, a global private investment manager. Mr. Ugwumba earned an MBA from the Johnson Graduate School of Management at Cornell University, and a BA in Political Science from Amherst College.

Stephen Zachary is a Partner and Portfolio Manager at Sands Capital and serves on the Boards of various therapeutics, diagnostics, and life sciences tools companies. Stephen received his PhD in Neuroscience from Johns Hopkins School of Medicine, and received a BA in Philosophy from Washington & Lee University. He is a member of the Kauffman Fellowship (Class 23).

Elena Shirokaya serves as Principal at IH International Advisors (“IHIA”). IHIA is part of a foundation-owned investment group, Interogo Holding AG, and provides private equity investment advisory services for a global and cross-sector portfolio covering investments in private equity funds, co-investments and direct investments. Ms. Shirokaya joined IHIA in 2012 and is based in London since 2018. Ms. Shirokaya leads sourcing and evaluating of private equity fund investments and co-investments in Europe and Asia. She holds various positions at LP advisory boards as part of IHIA’s portfolio management function. Prior to IHIA, Ms. Shirokaya was with Altran, now Capgemini Engineering and the Boston Consulting Group. She received MSc in Advanced Financial Economics from KU Leuven and MSc in Microfinance from Solvay Brussels School of Economics & Management.

Dr Xinhong Lim is a venture capital investor and award-winning scientist. He joined Vickers Venture Partners in 2015 and is based in Silicon Valley. He has led investments into companies in the life sciences, medical device, AI and advanced materials sectors, and advises on fund strategy in these areas. He serves as a director on the boards of Emergex (synthetic T-cell vaccines) and RWDC Industries (sustainable biopolymers), and as an observer on the boards of Aardvark (metabolic and inflammatory disease therapeutics), Lumitron (extremely brilliant Compton X-ray light sources), Sisaf (silicon-stabilized lipid nanoparticles for RNA delivery) and Biosplice (RNA-splicing modulatory therapeutics). He is Chief Strategy Officer of RWDC.

Dr Lim received his Ph.D. in Developmental Biology from Stanford University under the tutelage of Breakthrough Prize winner Professor Roel Nusse, a pioneer of Wnt signaling biology, and obtained a Certificate in Innovation and Entrepreneurship from the Stanford Graduate School of Business. He received a B.S. in Biochemistry from the University of Wisconsin-Madison, where he graduated with Highest Distinction. Dr Lim is an Assistant Professor (Adjunct) at the Skin Research Institute of Singapore (SRIS) and NTU LKC School of Medicine. He has served as an invited speaker for many international professional and scientific conferences and has been the principal investigator for more than $15 million of research grants. Dr Lim’s work has been published and cited in the most prestigious scientific journals, including Nature and Science, as well as highlighted in the international press, including by CNN and BBC. He is the recipient of numerous awards, including the Singapore National Academy of Sciences Young Scientist Award and the Ten Outstanding Young Singaporeans Award (Medical Innovation).